The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Global Histone Modifications Predict Prognosis of Resected Non–Small-Cell Lung Cancer
Abstract
Purpose: Epigenetic modifications may contribute to the development and progression of cancer. We investigated whether epigenetic changes involving multiple histones influence prognosis of non–small-cell lung cancer (NSCLC) patients. Patients and Methods: We used immunohistochemistry to assess histone 3 lysine 4 dimethylation (H3K4diMe), and acetylation of histone 2A lysine 5 (H2AK5Ac), histone 2B lysine 12, histone 3 lysine 9 (H3K9Ac), and histone 4 lysine 8 in resected tumor samples of 138 NSCLC patients. Data were analyzed using a recursive partitioning analysis (RPA). Results: The RPA classified the patients into seven distinct prognostic groups based on TNM stage (first node), histology, and histone modifications: H3K4diMe (< or ≥ 85% tumor cells), H3K9Ac (< or ≥ 68% tumor cells), and H2AK5Ac (< or ≥ 5% tumor cells). The seven groups were associated with significantly different disease-free (P < .0001) and overall survival (P < .0001). Interestingly, the four groups determined by stage I patients (below the first node) displayed dramatic differences in survival (median, 10 months in adenocarcinoma patients with H3K9Ac ≥ 68% v 147 months in nonadenocarcinoma patients with H3K4diMe ≥ 85%). A Cox model retained age and RPA groups as the sole independent factors significantly influencing overall survival. Conclusion: The prognostic influence of epigenetic changes involving multiple histones, in particular H2A and H3, is greater in early NSCLC, and evaluation of these changes may help in selecting early-stage NSCLC patients for adjuvant treatment. Our observations provide a rationale for the use of a combination of standard chemotherapy with drugs interacting with histone modifications, such as histone deacetylase inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
A Genomic Strategy to Refine Prognosis in Early-Stage Non–Small-Cell Lung Cancer
Potti, A., Mukherjee, S., Petersen, R., Dressman, H. K., Bild, A., Koontz, J., Kratzke, R., Watson, M. A., Kelley, M., Ginsburg, G. S., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060467 · Cited by 576
RetractedThe fundamental role of epigenetic events in cancer
Jones, P. A., & Baylin, S. B. (2002) · Nature Reviews Genetics · doi:10.1038/nrg816 · Cited by 5,648
Revisions in the International System for Staging Lung Cancer
Mountain, C. F. (1997) · Chest · doi:10.1378/chest.111.6.1710 · Cited by 4,565
Cancer epigenomics: DNA methylomes and histone-modification maps
Esteller, M. (2007) · Nature Reviews Genetics · doi:10.1038/nrg2005 · Cited by 2,146
Global histone modification patterns predict risk of prostate cancer recurrence
Seligson, D. B., Horvath, S., Shi, T., Yu, H., Tze, S., Grunstein, M., & Kurdistani, S. K. (2005) · Nature · doi:10.1038/nature03672 · Cited by 1,092
Travis, W. D., Travis, L. B., & Devesa, S. S. (1995) · Cancer · doi:10.1002/1097-0142(19950101)75:1+<191::aid-cncr2820751307>3.0.co;2-y · Cited by 582
Lund, A. H., & van Lohuizen, M. (2004) · Genes & Development · doi:10.1101/gad.1232504 · Cited by 489
Recursive Partitioning in the Health Sciences
Zhang, H., & Singer, B. (1999) · Statistics for Biology and Health · doi:10.1007/978-1-4757-3027-2 · Cited by 451
Strauss, G. M., Herndon, J. E., Maddaus, M. A., Johnstone, D. W., Johnson, E. A., Watson, D. M., Sugarbaker, D. J., Schilsky, R. L., & Green, M. R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.7019 · Cited by 380
Epigenetic and Chromatin Modifiers As Targeted Therapy of Hematologic Malignancies
Bhalla, K. N. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.16.600 · Cited by 308
Fry, W. A., Phillips, J. L., & Menck, H. R. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19991101)86:9<1867::aid-cncr31>3.0.co;2-9 · Cited by 263
Zhu, C.-Q., Shih, W., Ling, C.-H., & Tsao, M.-S. (2006) · Journal of Clinical Pathology · doi:10.1136/jcp.2005.031351 · Cited by 187
Strauss, G. M., Herndon, J. E., Maddaus, M. A., Johnstone, D. W., Johnson, E. A., Watson, D. M., Sugarbaker, D. J., Schilsky, R. A., Vokes, E. E., & Green, M. R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.7007 · Cited by 178
Histone-Deacetylase Inhibitors for the Treatment of Cancer
Lindemann, R. K., Gabrielli, B. G., & Johnstone, R. W. (2004) · Cell Cycle · doi:10.4161/cc.3.6.927 · Cited by 168
The necessity of a human epigenome project
Esteller, M. (2006) · Carcinogenesis · doi:10.1093/carcin/bgl033 · Cited by 166
Reid, T., Valone, F., Lipera, W., Irwin, D., Paroly, W., Natale, R., Sreedharan, S., Keer, H., Lum, B., Scappaticci, F., et al. (2004) · Lung Cancer · doi:10.1016/j.lungcan.2004.03.002 · Cited by 159
Histone modifying and chromatin remodelling enzymes in cancer and dysplastic syndromes
Gibbons, R. J. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi106 · Cited by 155
Lu, C. S., Soria, J., Tang, X., Xu, X.-C., Wang, L., Mao, L., Lotan, R., Kemp, B. L., Bekele, B. N., Feng, L., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.01.091 · Cited by 151
Tumor-Specific Methylation in Bronchial Lavage for the Early Detection of Non-Small-Cell Lung Cancer
Kim, H., Kwon, Y. M., Kim, J. S., Lee, H., Park, J., Shim, Y. M., Han, J., Park, J., & Kim, D.-H. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.077 · Cited by 146
QuantitativeRARβ2Hypermethylation
Jerónimo, C., Henrique, R., Hoque, M. O., Ribeiro, F. R., Oliveira, J., Fonseca, D., Teixeira, M. R., Lopes, C., & Sidransky, D. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0643 · Cited by 133
The Clinical Application of Targeting Cancer through Histone Acetylation and Hypomethylation
Gilbert, J., Gore, S. D., Herman, J. G., & Carducci, M. A. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0297 · Cited by 121
Pauer, L., Olivares, J., Cunningham, C. C., Williams, A., Grove, W. R., Kraker, A. J., Olson, S. C., & Nemunaitis, J. J. (2004) · Cancer Investigation · doi:10.1081/cnv-200039852 · Cited by 106
Chüeh, A. C., Wong, L. H., Wong, N. C., & Choo, K. H. A. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddi008 · Cited by 85
Digel, W., & Lübbert, M. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2005.02.002 · Cited by 79
Moinpour, C. M., Wu, J., Donaldson, G. W., Liepa, A. M., Melemed, A. S., O’Shaughnessy, J., Rappold, E., & Albain, K. S. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.621 · Cited by 51
Zaykin, D. V., & Young, S. S. (2005) · Pharmacogenomics · doi:10.1517/14622416.6.1.77 · Cited by 18
Young, S. S., & Ge, N. (2005) · Pharmacogenomics · doi:10.1517/14622416.6.1.65 · Cited by 15
Cited by
Histone methylation: a dynamic mark in health, disease and inheritance
Greer, E. L., & Shi, Y. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3173 · Cited by 2,241
Metabolic reprogramming and epigenetic modifications on the path to cancer
Sun, L., Zhang, H., & Gao, P. (2022) · Protein & Cell · doi:10.1007/s13238-021-00846-7 · Cited by 770
Elsheikh, S. E., Green, A. R., Rakha, E. A., Powe, D. G., Ahmed, R. A., Collins, H. M., Soria, D., Garibaldi, J. M., Paish, C. E., Ammar, A. A., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3907 · Cited by 511
Global Levels of Histone Modifications Predict Prognosis in Different Cancers
Seligson, D. B., Horvath, S., McBrian, M. A., Mah, V., Yu, H., Tze, S., Wang, Q., Chia, D., Goodglick, L., & Kurdistani, S. K. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.080874 · Cited by 508
Cancer epigenomics: beyond genomics
Sandoval, J., & Esteller, M. (2012) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2012.02.008 · Cited by 474
Metadata
- Authors
- Barlési, F., Giaccone, G., Gallegos-Ruiz, M. I., Loundou, A., Span, S. W., Lefesvre, P., Kruyt, F. A. E., & Rodriguez, J. A.
- Venue
- Journal of Clinical Oncology
- Published
- 2007-10-01
- Volume
- 25
- Issue
- 28
- Pages
- 4358-4364
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2158981924
- Cited by
- 280
- References
- 27
- FWCI
- 5.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.